This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignees: Agency for Science, Technology and Research, Singapore Health Services Pte Ltd, Tessa Therapeutics Pte. Ltd. Active years: 2019.
Company Filing History:
1 out of 1,557 
1 out of 140 
1 out of 3 Years Active: 2019
Title: Han Chong Toh: Innovator in Immunotherapy
Introduction
Han Chong Toh is a notable inventor based in Singapore, SG. He has made significant contributions to the field of immunotherapy, particularly in the treatment of Epstein-Barr virus-positive cancer. His innovative approach has the potential to improve patient outcomes and enhance the effectiveness of cancer treatments.
Latest Patents
Han Chong Toh holds a patent for a method for treating Epstein-Barr virus-positive cancer with immunotherapy. This patent, titled "Method for treating Epstein-Barr virus-positive cancer with immunotherapy," outlines a process for predicting whether a patient will be a long-term survivor on treatment of a disease by adoptive cell transfer (ACT). The method involves analyzing a blood-derived sample from the patient for one or more prognostic markers of long-term survival on treatment by ACT. Based on this analysis, the method predicts the likelihood of the patient being a long-term survivor. Additionally, the patent includes methods for treating patients by ACT and selecting patients for treatment.
Career Highlights
Throughout his career, Han Chong Toh has worked with prominent organizations in the healthcare sector. He has been associated with Tessa Therapeutics Pte. Ltd and Singapore Health Services Pte Ltd. His work in these companies has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Han Chong Toh has collaborated with notable professionals, including John Edward Connolly and Richard Hopkins. These collaborations have further enriched his research and development efforts in immunotherapy.
Conclusion
Han Chong Toh is a distinguished inventor whose work in immunotherapy has the potential to transform cancer treatment. His innovative methods and collaborations highlight his commitment to advancing medical science and improving patient care.